Fagron specializes in pharmaceutical compounding: raw materials, equipment and services that enable pharmacies and hospitals to prepare personalized medicines. It supplies active pharmaceutical ingredients, vehicles and related products for customized dosage forms worldwide. The niche is personalized and sterile compounding rather than branded blockbuster drugs.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 683.9 | — | 69.6 | — |
| 2023 | 763 | 11.6% | 70.5 | 1.3% |
| 2024 | 872 | 14.3% | 80.5 | 14.2% |
| 2025 | 952.2 | 9.2% | 91 | 13% |
All markets — KeepWinning global stock screener
Other companies on Euronext Brussels: Gimv NV (GIMB), Fluxys Belgium SA (FLUX), Montea Comm. VA (MONT), Orange Belgium S.A. (OBEL), Spadel SA (SPA), Tessenderlo Group NV (TESB)